HYHongmei Yuan

Hongmei Yuan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hongmei Yuan has a total of 52 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Emerging antibody-drug conjugate (ADC) therapies: perspectives from the global patent landscape

    by Tong Wu, Baijun Liu, Jiayu Jin, Yajie Zhou, Hongmei Yuan

    Background: Antibody-drug conjugates (ADCs) represent one of the most significant innovations in biopharmaceutical research, integrating antibody target specificity with the cytotoxic potency of small-molecule payloads. Despite rapid progress, the technological structure and knowledge dynamics underlying ADC innovation remain insufficiently characterized. This study aimed to map the ADC technological landscape through patent analysis of 6,620 patent families published before 30 June 2025. Method: BERTopic was applied to extract global topics, and characterize the ADC knowledge structure. A directed patent citation network was constructed at the patent family level, and patent citations were aggregated by dominant topic to establish a topic citation network. Degree-based and PageRank metrics were used to identify key topics and evaluate their functional roles in knowledge flow. Results: The analysis categorized 47 technological topics into nine clusters covering Target Selection, Biological Mechanisms, Antibody Structure, Therapeutic Indications, Conjugation Chemistry, Linker Chemistry, Payload Modality, Delivery Systems, Formulations and Stability. Ten key topics were identified as hubs within the topic citation network, comprising five target topics: B-cell surface antigens, B7 family antigens, Mesothelin, AXL, and HER family receptors; two payload topics: PBD payloads and Camptothecin-derived payloads; two mechanism topics: Interleukin immunocytokine and Immune checkpoint modulation, and one delivery topic: Nanoparticle delivery. Topic role analysis indicated distinct patterns among absorption-oriented, diffusion-oriented, and bridging topics in shaping knowledge absorption, dissemination, and trans-topic reorganization. Conclusion: This study provides an evidence-based view of the ADC patent landscape and offers strategic insights for target prioritization, payload design, and R&D planning. It also demonstrates the applicability of integrated patent landscape analysis to other emerging technology fields.

  • Trends and Hotspots in the Convergence of Artificial Intelligence and Cell and Gene Therapy: A Patent Analysis

    by Hongmei Yuan, Yuandong He, Cuiyan Wang, Baijun Liu

    Introduction: The convergence of Artificial Intelligence (AI) and Cell and Gene Therapy (CGT) represents a frontier in next-generation therapeutic innovation, yet the structural patterns of technology convergence within this interdisciplinary field remain poorly characterized. This study aims to develop a computational framework for predicting which technology linkages are most likely to strengthen within this convergence landscape, thereby providing a data-driven basis for R&D resource allocation. Method: Global patent data in the AI-CGT field were collected to construct a time-series heterogeneous network in which International Patent Classification (IPC) codes serve as technology nodes and individual patents as knowledge nodes, capturing co-occurrence, affiliation, and citation relationships among technologies. At the macro forecasting level, a Temporal Heterogeneous Graph Neural Network (THGNN) was employed for link prediction. The model aggregated multi-hop neighbor information through meta-paths and leveraged Long Short-Term Memory (LSTM) networks to capture technological evolution dynamics, with the aim of identifying IPC pairs with the highest future association weights. At the micro-analysis level, Latent Dirichlet Allocation (LDA) topic modeling was applied to patents associated with the core IPC pairs. The optimal number of topics was determined by combining perplexity curves with inter-topic distance visualization to reveal the key technological content of these IPC associations. Result: The temporal heterogeneous graph neural network model achieved an Area Under the Curve (AUC) of 0.7539, Average Precision (AP) of 0.7862, and F1 score of 0.7568 for link prediction. Based on this model, multiple high-confidence convergence pathways were identified, among which the predicted potential for association strengthening between biochemical detection (C12Q1) and neural networks (G06N3) and between genetic engineering (C12N15) and neural networks (G06N3) received the highest prediction scores (0.89 and 0.80, respectively), suggesting that these pairs are likely to constitute the primary axes of technology convergence in this field. Discussion: The two major convergence directions identified above correspond to the core bottlenecks in CGT clinical translation—namely, the precision and safety of gene editing, and the quality control and efficacy monitoring of therapeutic products. These findings reveal a patent-based convergence landscape in which AI-related patent classifications increasingly co-occur with both detection and therapeutic methods, indicating a trend of AI integration across the diagnostic-totherapeutic continuum at the level of patent disclosures. The identified convergence directions are computational predictions based on patent co-occurrence patterns and carry inherent uncertainty; they represent technology convergence signals rather than confirmed implementation. The "macroprediction– micro-analysis" bi-level framework proposed in this study provides a quantifiable, interpretable, and transferable analytical paradigm for technology opportunity identification in interdisciplinary pharmaceutical research. Conclusion: This study introduces THGNN into technology opportunity prediction in the AI-CGT convergence field and establishes a complete analytical chain from macro-level association identification to micro-level technology interpretation through LDA topic modeling. The findings offer a data-driven decision-making reference for pharmaceutical companies and research institutions seeking to strategically position their R&D pipelines within complex technology landscapes.

  • Open Access

    Integrated WGCNA of lncRNA-mRNA Networks Identifies Novel Hub Genes and Potential Therapeutic Agents for Liver Cirrhosis via Molecular Docking Validation

    by Tong Wu, Jiayu Jin, Yuhan Yang, Jing Sui, Yajie Zhou, Hongmei Yuan

    Liver cirrhosis (LC) is a complex pathological condition characterized by extensive transcriptomic reprogramming, yet the regulatory role of non-coding RNAs in disease progression remains poorly understood. This study aimed to systematically investigate long non-coding RNA (lncRNA)-messenger RNA (mRNA) interaction networks in LC through weighted gene co-expression network analysis (WGCNA). Gene expression profiles from datasets GSE197406, GSE107170, and GSE17548 were retrieved from the Gene Expression Omnibus (GEO) database, and differentially expressed lncRNAs and mRNAs were identified. Co-expression modules were constructed using WGCNA. Furthermore, functional enrichment analyses were conducted and drug repurposing opportunities were evaluated. Additionally, lncRNA-mRNA co-expression networks and lncRNA-mRNA-pathway networks were constructed to identify key regulatory relationships. Molecular docking simulations were subsequently performed to validate potential drug–target interactions. The results revealed several co-expression modules significantly associated with LC, particularly the turquoise module (r = 0.81). Genes within this module were enriched in several biological pathways, including the PI3K-Akt signaling pathway, NF-κB signaling pathway, and chemokine signaling pathway. The hub lncRNA in the turquoise module, NONHSAT134945.2, was found to be co-expressed with mRNAs involved in inflammasome-mediated pyroptosis and hepatocyte activation, such as CSF1R, HCK, and CASP1. Based on this hub gene signature, AB-1010, GW768505A, and Dasatinib were identified as potential therapeutic candidates. Molecular docking analysis confirmed that these compounds exhibit high binding affinity to CSF1R and HCK, with all interatomic distances maintained below 3.5 Å. These findings provide new insights into the molecular mechanisms underlying LC and suggest that the NONHSAT134945.2–CSF1R/HCK axis may serve as a valuable target for future translational research and therapeutic development.

  • Open Access

    Cost-utility analysis of omalizumab for the treatment of chronic spontaneous urticaria in China

    by Yueyang Huang, Hongmei Yuan, Zhe Huang

    Chronic spontaneous urticaria (CSU) is a common inflammatory immune skin disease. It has a serious impact on the patients’ quality of life and imposes a serious financial burden on patients. The standard therapy for CSU (using antihistamines), while less costly, has limited efficacy and no longer adequately meets the clinical needs of CSU patients. Omalizumab is the world’s first and currently the only biologic approved for the treatment of CSU. Several studies have confirmed the efficacy and safety of omalizumab for CSU. However, the economics of omalizumab treatment relative to standard therapies remains unknown in China. The purpose of this study was to analyze the cost-effectiveness of omalizumab versus standard treatments for CSU after omalizumab’s inclusion in the National Drug Insurance List from the patient’s perspective. We developed a Markov model based on the Urticaria Activity Score over 7 days (UAS7). The modeling period was 4 weeks. The time horizon was 10 years. The willingness-to-pay threshold (WTP) of 1–3 times gross domestic product (GDP) per capita was selected. Incremental cost-effectiveness ratio (ICER) was calculated from the base-case analysis, and one-way sensitivity analysis and probabilistic sensitivity analysis were performed. The ICER of omalizumab treatment relative to standard treatment was ¥160,411/QALY, which was between 1 and 3 times GDP per capita. Sensitivity analyses illustrated that the direct cost of omalizumab had a significant effect on the ICER and demonstrated the stability of the results. Omalizumab treatment is a cost-effective regimen compared with standard therapy under certain circumstances. This demonstrates the important role that health insurance policies play in reducing the burden on CSU patients. However, the limitations of applying foreign clinical data in this paper and the uncertainty of cost-effectiveness at a low WTP threshold are two aspects that cannot be ignored, and subsequent related studies are needed. This study will help patients to make decisions about treatment options, and will be a reference to relevant healthcare organizations.


  • Open Access

    Cost-effectiveness analysis of ambroxol for the treatment of Chinese patients with Gaucher disease

    by Yueyang Huang, Hongmei Yuan, Zhe Huang

    Background: Gaucher disease (GD) is an autosomal recessive disorder with a wide range of clinical symptoms that cause abnormal function of parenchymal organs such as liver and spleen in patients. Enzyme replacement therapy, represented by imiglucerase, is a common approach for GD treatment. However, limited efficacy and high cost are important factors restricting its use. Ambroxol has gradually attracted attention due to its ease of administration, safety, and efficacy. However, there is no pharmacoeconomic evaluation of ambroxol for the treatment of GD in China. The cost-effectiveness profile of ambroxol combined with imiglucerase therapy for the treatment of GD, as opposed to imiglucerase monotherapy, needs to be investigated.Objective: This study aimed to analyze the cost-effectiveness of ambroxol for GD in China from the perspective of the Chinese healthcare system.Methods: We constructed an eight-state Markov model based on the disease characteristics of GD. The Markov cycle was 1 month. The time horizon was 6 years. The willingness-to-pay threshold was chosen to be 1–3 times the gross national product (GDP) per capita. The incremental cost-effectiveness ratio (ICER) was calculated from the base-case analysis, and one-way sensitivity analyses and probabilistic sensitivity analyses were performed.Results: The ICER value was ¥223,726.70, which was between 1 and 3 times GDP per capita. Sensitivity analysis showed that the cost of imiglucerase had a significant effect on ICER as well as demonstrating the stability of the results.Conclusion: Ambroxol combination therapy is a cost-effective regimen compared with imiglucerase monotherapy.


  • Open Access

    Cost-effectiveness analysis of enzyme replacement therapy for the treatment of Chinese patients with fabry disease: a Markov model

    by Yueyang Huang, Hongmei Yuan, Zhe Huang

    Background: Fabry disease (FD) is an X-chromosome-linked genetic disorder. Currently, the main treatments for FD include disease-nonspecific and disease-specific treatments. Nonspecific treatment involves symptomatic management of organ involvement. On the other hand, disease-specific treatment is to regulate the activity of the corresponding enzymes, which is targeted. Among them, enzyme replacement therapy (ERT) is a classical therapy. Several studies have demonstrated the significant ameliorative effect of agalactosidase-α (ALTA-a) on cardiac and renal function in patients with FD. Despite the excellent clinical performance, there are limited pharmacoeconomic studies on ERT for FD worldwide.Objective: The aim of this study was to analyze the cost-effectiveness of ERT for FD in China from the perspective of the healthcare system.Methods: We constructed a five-state Markov model based on the disease characteristics of FD. The modeling period was 1 month. The time horizon was 3 years. The willingness-to-pay threshold was chosen as 1-3 times the gross national product (GDP) per capita. The incremental cost-effectiveness ratio (ICER) was calculated from the base case analysis, and one-way sensitivity analysis and probabilistic sensitivity analysis were performed.Results: The ICER value is ¥148071.95/QALY, which is between 1-3 times GDP per capita. The sensitivity analysis showed that the cost of ALTA-a had a significant effect on ICER and proved the stability of the results.Conclusion: ERT therapy is a cost-effective program compared to “No ERT” therapy.


  • Open Access

    Responsive nanomaterials in biomedicine, patent path and prospect analysis

    by Xinrui Liu, Hongmei Yuan

    In recent years, responsive nanomaterials have demonstrated tremendous potential in biomedical applications due to their unique advantages in precise drug delivery and controlled release. For complex diseases such as cancer, chronic inflammation, and genetic disorders, traditional treatment methods are often limited by insufficient targeting and significant side effects. Responsive nanotechnology, by sensing specific internal or external stimuli, has significantly enhanced the precision and efficiency of treatments. This study systematically summarizes the technological trajectory and emerging research directions of responsive nanomaterials through global patent and literature data, employing main path analysis, derivative path analysis, and keyword co-occurrence analysis. The results reveal the evolution of this field, from the optimization of early single-stimulus-responsive nano delivery systems to the rise of theranostics integration, followed by advancements in multi-stimuli-responsive synergistic therapies, and finally, the innovation in biomimetic material design. Each developmental phase has increasingly focused on adapting to complex biological environments, achieving superior targeting performance, and enhancing therapeutic efficacy. Keyword co-occurrence analysis highlights key research hotspots, including biomimetic design, multimodal synergistic therapies, and emerging response mechanisms. In the future, responsive nanomaterials are expected to play a pivotal role in personalized medicine, multifunctional carrier design, and complex disease management, providing novel insights and technological support for precision medicine.